Lannett On Track To Launch Insulin Glargine By 2023
Company Expects Pivotal Trial For Lantus Biosimilar To Start In 2022
After receiving feedback from the FDA, Lannett has announced that it is on track to submit an investigational new drug application for its insulin glargine candidate to the agency later in 2021. Following this, the company plans to file a biologics license application in 2022 and launch the product in 2023.
